Sino Biopharm Gets China Nod for Soft Mist Inhalation Formulation Trial

MT Newswires Live
Aug 05

Sino Biopharmaceutical (HKG:1177) obtained clinical trial approval for TQC3302, a soft mist inhalation formulation, from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.

The inhalation formulation is intended for the maintenance treatment of chronic obstructive pulmonary disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10